holdings2017bb – Page 6

Gauteng Premier’s visit to Aspen is set to boost export growth

May 7, 2015

07/05/15: Clayville, Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the 5th largest generic company in the world, earlier today hosted a delegation of over 30 government dignitaries at its manufacturing facility where specialised infant nutritional products are produced for local and export markets. The facility is unique in that it contains highly…

Aspen opposes violent attacks directed at fellow African migrants

April 28, 2015

28/04/15: Statement by Stephen Saad, Group CEO, Aspen Pharmacare Holdings Ltd “Aspen” on the violent attacks directed at fellow African migrants living in South Africa Durban – Aspen, largest producer and supplier of medicines to our African continent, in the strongest terms condemns the shameful and senseless harassment and violence directed at fellow African migrants,…

GSK announces completion of the sale of half its stake in Aspen

March 13, 2015

13/03/15: GlaxoSmithKline (“GSK”) has announced the completion of the disposal of half of its 12.4% shareholding in Aspen (equivalent to 28.2 million ordinary shares). These shares were sold by means of an accelerated book build offering process which resulted in the shares being sold at ZAR 372 per share, raising gross proceeds of approximately ZAR…

Aspen’s half-year gross revenue surges by 47% to R19 billion

March 5, 2015

05/03/15: Aspen’s half-year gross revenue surges by 47% to R19 billion Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the fifth largest generic company in the world, has announced stellar results for the six months ended 31 December 2014, which have primarily been driven by its offshore businesses. GROUP PERFORMANCE Gross revenue increased…

Acquisition of Rights to an Anti-Coagulant Product from Novartis

February 14, 2015

Aspen is pleased to announce that Aspen Global Incorporated (“AGI”), a wholly owned subsidiary of Aspen Holdings, has entered into an agreement with Novartis AG in term of which it will acquire the rights to Mono‐Embolex®, an injectable anti-coagulant, for a consideration of US$142.3 million. (Durban, 14 February 2015) Mono-Embolex is a heparin based anti-coagulant…

Acquisition of rights to an anti-coagulant product from Novartis

January 26, 2015

26/01/15: Aspen is pleased to announce that Aspen Global Incorporated (“AGI”), a wholly owned subsidiary of Aspen Holdings, has entered into an agreement with Novartis AG in terms of which it will acquire the rights to Mono-Embolex®, an injectable anti-coagulant, for a consideration of US$142.3 million. Mono-Embolex is a heparin based anti-coagulant sold in the…

2014 Anti-retroviral tender results

December 24, 2014

24/12/14: Following the announcement of the Anti-Retroviral (ARV) Tender results by the South African National Treasury Department, Aspen Pharmacare Holdings Limited is pleased to announce that its South African operating company (Pharmacare Limited t/a Aspen Pharmacare) has been successful in winning a number of key products in the tender Aspen’s award included 25% of the…

Aspen’s world class PE site manufactures and exports pharmaceutical products for global markets

November 17, 2014

17/11/14: Port Elizabeth. The Minister of Trade and Industry, Dr Rob Davies today visited the Aspen Pharmacare manufacturing site in Port Elizabeth, Eastern Cape. The purpose of the visit was to engage on the future direction and orientation of the Pharmaceutical Industry in South Africa. The visit was also for Minister Davies to see first-hand…

Stephen Saad’s Aspen: From JSE newcomer to R150bn valuation in 16 years

September 16, 2014

16/09/14: In 1998, Stephen Saad and Gus Attridge took their ambitions public through the reverse takeover by their year-old business into JSE-listed Medhold. A year later they pulled off a R2.4bn hostile takeover of the well resourced but poorly managed SA Druggists. And the rest is history. Now a multinational corporation, last week Aspen delivered another…

Aspen’s revenue soars by 53% to R29.5 billion

September 10, 2014

10/09/14: Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), the fifth largest generic company in the world and Africa’s largest pharmaceutical manufacturer, has announced excellent results for the year ended 30 June 2014. GROUP PERFORMANCE Revenue increased by 53% to R29.5 billion. Operating profit rose by 47% to R7.4 billion. Normalised headline earnings,…